Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective compassionate-use study of inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukemia
NL-OMON29610Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Preliminary efficacy and safety of inotuzumab ozogamicin, Safety and toxicities and 1 more. Started Dec 2018; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON29610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29610.